DK200301685A - Isolated polypeptide with hematopoietic biological properties such as naturally occurring hpG-CSF, DNA sequence encoding it, plasmids containing the sequence, transformed / transfected host cells, - Google Patents
Isolated polypeptide with hematopoietic biological properties such as naturally occurring hpG-CSF, DNA sequence encoding it, plasmids containing the sequence, transformed / transfected host cells, Download PDFInfo
- Publication number
- DK200301685A DK200301685A DK200301685A DKPA200301685A DK200301685A DK 200301685 A DK200301685 A DK 200301685A DK 200301685 A DK200301685 A DK 200301685A DK PA200301685 A DKPA200301685 A DK PA200301685A DK 200301685 A DK200301685 A DK 200301685A
- Authority
- DK
- Denmark
- Prior art keywords
- dna sequence
- naturally occurring
- transformed
- csf
- polypeptide
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title description 21
- 108090000765 processed proteins & peptides Proteins 0.000 title description 21
- 102000004196 processed proteins & peptides Human genes 0.000 title description 21
- 108091028043 Nucleic acid sequence Proteins 0.000 title description 9
- 230000003394 haemopoietic effect Effects 0.000 title description 4
- 230000004071 biological effect Effects 0.000 title description 3
- 239000013612 plasmid Substances 0.000 title description 2
- 210000004027 cell Anatomy 0.000 description 7
- 108091029865 Exogenous DNA Proteins 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
PATENTKRAV 1. Isoleret polypeptid med de hæmatοροίetiske biologiske egenskaber for naturligt forekommende plu-ripotent granulocyt kolonistimulerende faktor (hpG-CSF), hvor polypeptidet har en aminosyresekvens valgt blandt den i Tabel VII angivne polypeptidsekvens og en hvilken som helst allelisk variant, et derivat, en sletningsanalog, substitutionsanalog eller additionsanalog deraf, kendetegnet ved at være ikke naturligt forekommende og være et produkt af proka-ryotisk eller eukaryotisk ekspression af en exogen DNA-sekvens. 2. Ikke naturligt forekommende polypeptid ifølge krav 1, kendetegnet ved, at det kun består af den i Tabel VII angivne aminosyresekvens 1-174 . 3. Polypeptidanalog ifølge krav 1, kendetegnet ved, at den exogene DNA-sekvens er en cDNA-sekvens. 4. Polypeptidanalog ifølge krav 1, kendetegnet ved, at den exogene DNA-sekvens er en genomisk sekvens. 5. Polypeptidanalog ifølge krav 1, kendetegnet ved, at den exogene DNA-sekvens bæres af et autonomt replikerende DNA-plasmid eller viral vektor . 6. Polypeptid ifølge krav 1, kendetegnet ved at være kovalent associeret med en påviselig markørsubstans, især en radioaktiv markør. 7. DNA-sekvens, der ved eksprimering i en prokaryotisk eller eukaryotisk værtscelle koder for et polypeptidprodukt, der besidder i det mindste en del af den primære struktur og de hæmatopoietiske biologiske egenskaber for naturligt forekommende pluripo-tent granulocyt kolonistimulerende faktor, hvor DNA-sekvenden er kendetegnet ved at kode for et polypeptid med en aminosyresekvens valgt blandt den i Tabel VII angivne polypeptidsekvens og en hvilken som helst allelisk variant, et derivat, en sletningsanalog, substitutionsanalog eller additionsanalog deraf. 8. cDNA-sekvens ifølge krav 7. 9. Genomisk DNA-sekvens ifølge krav 7. 10. DNA-sekvens ifølge krav 7, kendetegnet ved, at den er kovalent associeret med en påviselig markørsubstans, især en radioaktiv markør . 11. Enkeltstrenget DNA-sekvens ifølge krav 10. 12. Biologisk funktionelt plasmid eller viral DNA-vektor, kendetegnet ved, at det inkluderer en DNA-sekvens ifølge krav 7. 13. Prokaryotisk eller eukaryotisk værtscelle, kendetegnet ved, at den er transformeret eller transficeret med en DNA-sekvens ifølge krav 7 på en sådan måde, at værtscellen kan eksprimere det pågældende polypeptidprodukt. 14. Prokaryotisk eller eukaryotisk værtscelle, kendetegnet ved, at den er stabilt transformeret eller transficeret med en DNA-vektor ifølge krav 12. 15. Værtscelle ifølge krav 13 eller 14, kendetegnet ved, at værten er E. coli. 16. Værtscelle ifølge krav 13 eller 14, kendetegnet ved, at værten er en pattedyrscelle. 17. Fremgangsmåde til fremstilling af isolerede polypeptider med de hæmatopoietiske egenskaber for naturligt forekommende human granulocyt kolonistimulerende faktor, hvor polypeptidet har en aminosyrese-kvens valgt blandt den i Tabel VII angivne polypep-tidsekvens og en hvilken som helst allelisk variant, en sletningsanalog, substitutionsanalog eller additionsanalog deraf, kendetegnet ved, at man under egnede næringsbetingelser dyrker prokaryotiske eller især eukaryotiske værtsceller, der er transformeret eller transficeret med en DNA-sekvens ifølge krav 7 på en sådan måde, at de kan eksprimere det nævnte polypeptid, og at man isolerer det ønskede po-lypeptidprodukt fra ekspressionen af DNA-sekvensen. 18. Farmaceutisk præparat, kendetegnet ved, at det omfatter en effektiv mængde af polypeptidet ifølge krav 1 og/eller fremstillet ifølge krav 17, og et farmaceutisk acceptabelt fortyndingsmiddel, adjuvans eller bærer. 19. Farmaceutisk præparat ifølge krav 18, yderligere kendetegnet ved at være frit for association med noget som helst humant protein. 20. Anvendelse af polypeptidet ifølge krav 1 til fremstilling af et lægemiddel til tilvejebringelse af hæmatopoietisk terapi på et pattedyr.PATENT REQUIREMENT 1. An isolated polypeptide having the hematοροίetic biological properties of naturally occurring pluripotent granulocyte colony-stimulating factor (hpG-CSF), wherein the polypeptide has an amino acid sequence selected from the polypeptide sequence specified in Table VII and any derivative allelic variant, deletion analogue, substitution analogue or addition analogue thereof, characterized by not being naturally occurring and being a product of prokaryotic or eukaryotic expression of an exogenous DNA sequence. Non-naturally occurring polypeptide according to claim 1, characterized in that it consists only of the amino acid sequence indicated in Table VII 1-174. The polypeptide analog of claim 1, characterized in that the exogenous DNA sequence is a cDNA sequence. The polypeptide analog of claim 1, characterized in that the exogenous DNA sequence is a genomic sequence. The polypeptide analog of claim 1, characterized in that the exogenous DNA sequence is carried by an autonomously replicating DNA plasmid or viral vector. A polypeptide according to claim 1, characterized by being covalently associated with a detectable marker substance, especially a radioactive marker. A DNA sequence which, upon expression in a prokaryotic or eukaryotic host cell, encodes a polypeptide product possessing at least a portion of the primary structure and hematopoietic biological properties of naturally occurring pluripotent granulocyte colony-stimulating factor, wherein the DNA sequence is characterized by encoding a polypeptide having an amino acid sequence selected from the polypeptide sequence set forth in Table VII and any allelic variant, a derivative, a deletion analog, a substitution analogue, or an addition analogue thereof. A cDNA sequence according to claim 7. A genomic DNA sequence according to claim 7. A DNA sequence according to claim 7, characterized in that it is covalently associated with a detectable marker substance, in particular a radioactive marker. A single-stranded DNA sequence according to claim 10. 12. Biologically functional plasmid or viral DNA vector, characterized in that it includes a DNA sequence according to claim 7. 13. Prokaryotic or eukaryotic host cell, characterized in that it is transformed or transfected with a DNA sequence according to claim 7 in such a way that the host cell can express the polypeptide product in question. A prokaryotic or eukaryotic host cell, characterized in that it is stably transformed or transfected with a DNA vector according to claim 12. A host cell according to claim 13 or 14, characterized in that the host is E. coli. Host cell according to claim 13 or 14, characterized in that the host is a mammalian cell. A method of producing isolated polypeptides having the hematopoietic properties of naturally occurring human granulocyte colony-stimulating factor, wherein the polypeptide has an amino acid sequence selected from the polypeptide sequence set forth in any of the polypeptide sequences and any allelic variant, a deletion analog, or substitution analog. addition analog thereof, characterized in that, under suitable nutritional conditions, prokaryotic or especially eukaryotic host cells transformed or transfected with a DNA sequence according to claim 7 are cultured in such a way that they can express said polypeptide and isolate the desired polypeptide product from the expression of the DNA sequence. Pharmaceutical composition, characterized in that it comprises an effective amount of the polypeptide of claim 1 and / or prepared according to claim 17, and a pharmaceutically acceptable diluent, adjuvant or carrier. The pharmaceutical composition of claim 18, further characterized by being free of association with any human protein. Use of the polypeptide of claim 1 for the manufacture of a medicament for providing hematopoietic therapy to a mammal.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK200301685A DK175551B1 (en) | 1985-08-23 | 2003-11-12 | Poly:peptide with granulocyte colony stimulating factor activity - obtd. by recombinant DNA procedures for treating haematopoietic disorders |
| DK200401111A DK176002B1 (en) | 1985-08-23 | 2004-07-15 | Poly:peptide with granulocyte colony stimulating factor activity - obtd. by recombinant DNA procedures for treating haematopoietic disorders |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76895985A | 1985-08-23 | 1985-08-23 | |
| US76895985 | 1985-08-23 | ||
| US83554886 | 1986-03-03 | ||
| US06/835,548 US4810643A (en) | 1985-08-23 | 1986-03-03 | Production of pluripotent granulocyte colony-stimulating factor |
| DK204487 | 1987-04-22 | ||
| DK198702044A DK174980B1 (en) | 1985-08-23 | 1987-04-22 | Isolated polypeptide having properties such as hpG-CSF, DNA sequence encoding it, plasmids containing the sequence, transformed / transfected host cells, method for producing the polypeptide, pharmaceutical composition containing it ... |
| DK200301685A DK175551B1 (en) | 1985-08-23 | 2003-11-12 | Poly:peptide with granulocyte colony stimulating factor activity - obtd. by recombinant DNA procedures for treating haematopoietic disorders |
| DK200301685 | 2003-11-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK200301685A true DK200301685A (en) | 2003-11-12 |
| DK175551B1 DK175551B1 (en) | 2004-12-06 |
Family
ID=29715751
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK200301684A DK175466B1 (en) | 1985-08-23 | 2003-11-12 | Poly:peptide with granulocyte colony stimulating factor activity - obtd. by recombinant DNA procedures for treating haematopoietic disorders |
| DK200301683A DK175465B1 (en) | 1985-08-23 | 2003-11-12 | Poly:peptide with granulocyte colony stimulating factor activity - obtd. by recombinant DNA procedures for treating haematopoietic disorders |
| DK200301685A DK175551B1 (en) | 1985-08-23 | 2003-11-12 | Poly:peptide with granulocyte colony stimulating factor activity - obtd. by recombinant DNA procedures for treating haematopoietic disorders |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK200301684A DK175466B1 (en) | 1985-08-23 | 2003-11-12 | Poly:peptide with granulocyte colony stimulating factor activity - obtd. by recombinant DNA procedures for treating haematopoietic disorders |
| DK200301683A DK175465B1 (en) | 1985-08-23 | 2003-11-12 | Poly:peptide with granulocyte colony stimulating factor activity - obtd. by recombinant DNA procedures for treating haematopoietic disorders |
Country Status (1)
| Country | Link |
|---|---|
| DK (3) | DK175466B1 (en) |
-
2003
- 2003-11-12 DK DK200301684A patent/DK175466B1/en not_active IP Right Cessation
- 2003-11-12 DK DK200301683A patent/DK175465B1/en not_active IP Right Cessation
- 2003-11-12 DK DK200301685A patent/DK175551B1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DK175551B1 (en) | 2004-12-06 |
| DK200301683A (en) | 2003-11-12 |
| DK175465B1 (en) | 2004-11-01 |
| DK200301684A (en) | 2003-11-12 |
| DK175466B1 (en) | 2004-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hapel et al. | Biologic properties of molecularly cloned and expressed murine interleukin-3 | |
| CA1341590C (en) | Human immune interferon | |
| NO20032250L (en) | Use of a hpG-CSF polypeptide for the preparation of a drug for arresting the proliferation of leukemia cells | |
| KR920701238A (en) | Hepatocellular factor for treating blood cell related diseases, oligonucleotides encoding them, and methods for preparing the same, pharmaceutical compositions comprising the same | |
| DK167929B1 (en) | Recombinant DNA molecule CONTAINING ONE OF HESTEINTERFERONER CODING SEQUENCE, TRANSFORMED host organism CONTAINING DNA molecule INTERFERON encoded by the recombinant DNA molecule, METHOD FOR PRODUCTION OF HESTEINTERFERONER, USE OF interferons MEANS OF THERAPEUTIC TREATMENT AND HORSES-INTERFERON FOR USE AS PHARMACEUTICAL PRODUCT | |
| AU2018372167A1 (en) | Partial agonists of interleukin-2 | |
| CA2268023A1 (en) | Circularly permuted polypeptides as novel stem cell factor receptor agonists | |
| SK414191A3 (en) | Human interleukin-4 | |
| KR950704356A (en) | Progenitor B CELL STIMULATING FACTOR | |
| CA2134030A1 (en) | Soluble interferon .alpha.-receptor, its preparation and use | |
| CA2268027A1 (en) | Novel flt-3 receptor agonists | |
| DK200301685A (en) | Isolated polypeptide with hematopoietic biological properties such as naturally occurring hpG-CSF, DNA sequence encoding it, plasmids containing the sequence, transformed / transfected host cells, | |
| Krämmer et al. | A plasmodial α-tubulin cDNA from Physarum polycephalum: nucleotide sequence and comparative analysis | |
| US6090378A (en) | Composition comprising interleukin-2 and thymidine kinase for the treatment of tumors | |
| EP0546099B1 (en) | Use of human Interferon gamma 4-134 | |
| BR9708648B1 (en) | polypeptide, dna molecule, vector, process for polypeptide production, and pharmaceutical composition. | |
| Kametaka et al. | Reduction of CTLL‐2 cytotoxicity by induction of apoptosis with a Fas‐estrogen receptor chimera | |
| JP3689111B2 (en) | Interleukin 15 | |
| MXPA99003875A (en) | NOVEL flt-3 RECEPTOR AGONISTS | |
| GEP19991639B (en) | DNA-Sequence, Cell, Vector, Polypeptide, Method for Obtaining and Pharmaceutical Formulation | |
| RU99123374A (en) | Polypeptide DNA sequence CELL, METHOD FOR PRODUCING FACTOR STEM CELLS, COMPOSITIONS, METHODS OF TREATMENT AND A METHOD PAINTS grafting bone marrow, METHOD FOR AMPLIFICATION RESTORATION OF BONE MARROW, antibodies, methods for isolating stem cell factor, METHOD FOR PRODUCING POLYMER-PEPTIDE adduct transfection techniques, METHOD GENE TRANSFER | |
| KR20010022127A (en) | Production of human mutant proteins in human cells by homologous recombination | |
| KASHIMA et al. | Role of unique consecutive glutamine repeats in active murine interleukin-2 molecule | |
| RU97115995A (en) | MUTANT PROTEINS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUP | Patent expired |